Cerebrolysin
Synthetic peptide studied in clinical and preclinical models for neurotrophic support and synaptic plasticity enhancement
Last updated: March 1, 2026
- Compound
- Cerebrolysin
- Class
- Cognitive peptide
- Summary
- Synthetic peptide studied in clinical and preclinical models for neurotrophic support, synaptic plasticity enhancement, neuroprotection against excitotoxicity.
- Mechanism
- Neuroinflammation Modulation
- Research Status
- Phase III
- Routes Studied
- Intramuscular or intravenous injection
- Evidence Level
- Late-stage clinical · Clinically tested
What Should You Know About Cerebrolysin?
- What is Cerebrolysin?
- Cerebrolysin is a synthetic peptide studied in clinical and preclinical models for neurotrophic support and synaptic plasticity enhancement.
- Is Cerebrolysin clinically proven?
- No. Human evidence remains limited and does not establish Cerebrolysin as clinically proven.
- What has Cerebrolysin been studied for?
- Cerebrolysin has been studied in clinical and preclinical settings of neurotrophic support, synaptic plasticity enhancement, neuroprotection against excitotoxicity. Late-stage clinical trials have been conducted, though final regulatory outcomes may vary by jurisdiction.
- Is Cerebrolysin approved?
- Cerebrolysin is in late-stage clinical development but has not yet received full regulatory approval in all jurisdictions. Consult a local specialist for current status.
What Is Cerebrolysin?
Cerebrolysin is a unique multi-peptide neurotrophic complex consisting of low-molecular-weight neuropeptides and free amino acids derived from purified porcine brain proteins through a standardized biotechnological process. Unlike single-molecule peptide therapeutics, Cerebrolysin contains a defined mixture of biologically active peptide fragments that collectively mimic the activity of endogenous neurotrophic factors, including brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF). This...
Evidence Summary
Cerebrolysin has reached late-stage clinical trials (Phase III). Substantial human data exists, though final regulatory outcomes may still be pending.
Evidence Breakdown
| Domain | Evidence Level |
|---|---|
| Neurotrophic Support | Limited |
| Synaptic Plasticity Enhancement | Limited |
| Neuroprotection Against Excitotoxicity | Limited |
| Neurogenesis Promotion | Limited |
| Human clinical evidence | Substantial |
| Safety data | Insufficient |
Editorial Position
Cerebrolysin is best understood as a compound with emerging clinical evidence that has not yet reached definitive conclusions. Many online claims exceed the strength of available human evidence, and safety data remains incomplete. Any consideration of this compound should involve careful evaluation of individual context and medical guidance.
Regulatory Status Snapshot
- Late-stage clinical trials conducted; not yet approved in all jurisdictions
- Safety data from clinical trials available but regulatory review ongoing
Need help interpreting this evidence for your situation?
Talk to a SpecialistA deep research review for Cerebrolysin is not yet available. This compound profile is based on published peer-reviewed references listed below.
Browse all research reviewsWhat Has Cerebrolysin Been Studied For?
Research areas where Cerebrolysin has been investigated in published studies
-
Neurotrophic Support Cerebrolysin has been studied in clinical and preclinical studies of neurotrophic support.
-
Synaptic Plasticity Enhancement Cerebrolysin has been studied in clinical and preclinical studies of synaptic plasticity enhancement.
-
Neuroprotection Against Excitotoxicity Cerebrolysin has been studied in clinical and preclinical studies of neuroprotection against excitotoxicity.
-
Neurogenesis Promotion Cerebrolysin has been studied in clinical and preclinical studies of neurogenesis promotion.
How Does Cerebrolysin Work?
These mechanisms have been studied in clinical and preclinical settings. Clinical trials are ongoing or completed.
- 01 TrkB Receptor Activation
- 02 Intracellular signaling
- 03 Glutamate Receptor Modulation
- 04 Neurogenesis Stimulation
Not sure if Cerebrolysin is right for you?
A specialist can review the evidence, evaluate your medical context, and help you make an informed decision about Cerebrolysin.
Community Reports (Anecdotal)
Experiences shared here are self-reported and do not represent clinical evidence.
Rate Cerebrolysin
How Is Cerebrolysin Administered?
Cerebrolysin is available via Intramuscular or intravenous injection. Appropriate use and protocol should be determined by a qualified specialist.
What Are the Specifications of Cerebrolysin?
What Conditions Has Cerebrolysin Been Linked To?
Have Questions About Cerebrolysin?
The active peptide components of Cerebrolysin have molecular weights below 10 kDa, which is small enough to cross the blood-brain barrier following parenteral administration.
Preclinical studies have demonstrated improvements in spatial memory (Morris water maze), object recognition, and fear conditioning paradigms following Cerebrolysin administration. These behavioral improvements correlate with increased dendritic spine density, elevated synaptic protein expression, and enhanced long-term potentiation.
Published studies on Cerebrolysin can be found on PubMed and other peer-reviewed databases. Our references section below lists key citations.
Ready to discuss Cerebrolysin with a specialist?
Get evidence-based guidance tailored to your health goals and medical context.
Book a Consultation Free initial consultation. No obligation.Reviewed by the Peptide Science Thailand Editorial Team.
Last reviewed: March 1, 2026